NetworkNewsBreaks – Cabaletta Bio Inc. (NASDAQ: CABA) Featured in Mizuho Securities Research Report
Cabaletta Bio (NASDAQ: CABA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Cabaletta's safety data from the second dose cohort at a dose of 100M DSG3-CAART cells in the DesCAARTes Phase 1 in mucosal pemphigus vulgaris continue to demonstrate no clinically relevant adverse events or DLTs observed during the 28-day monitoring period following infusion. We find today's announcement especially encouraging, as the data demonstrate the potential for persistent activity and dosing approaching that of oncology but without the need for preconditioning, which we believe makes the approach highly attractive for non-oncology…







